AAA
VIR icon

Affinity Asset Advisors’s Vir Biotechnology VIR Stock Holding History

Affinity Asset Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200,000
Closed -$1.78M – 107
2024
Q2 		$1.78M Buy
+200,000
New +$1.92M 0.21% 67
2023
Q3 		– Sell
-20,000
Closed -$491K – 92
2023
Q2 		$491K Buy
+20,000
New +$502K 0.17% 64

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Affinity Asset Advisors's VIR Position: Q3 2024 in Review

Affinity Asset Advisors sold out of Vir Biotechnology (VIR) in Q3 2024, closing a stake of 200,000 shares — an estimated $1.78M sold.

Affinity Asset Advisors first reported a position in VIR in Q2 2023 and held it in 2 quarters. The position peaked at $1.78M in Q2 2024. 197 funds tracked by Wall St. Rank hold VIR as of Q3 2024.

  • Affinity Asset Advisors reported no remaining Vir Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 200,000 Vir Biotechnology shares in Q3 2024, an estimated $1.78M.
  • Affinity Asset Advisors first reported a position in Vir Biotechnology in Q2 2023 and held it in 2 quarters.
  • Affinity Asset Advisors's Vir Biotechnology position peaked at $1.78M in Q2 2024.
  • 197 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2024.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.